Orticumab

DRUG3 trials

Sponsors

Abcentra LLC, Abcentra

Conditions

Acute Coronary SyndromesAtherosclerotic Cardiovascular diseaseAtherosclerotic Coronary Vascular DiseaseCardiometabolic SyndromeCoronary Arterial Disease (CAD)Coronary Artery DiseaseHeart DiseaseInflammation

Phase 2

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

CompletedNCT04776629

AbcentraCardiometabolic Syndrome, Coronary Artery Disease, Inflammation +1

Start: 2021-06-30End: 2022-11-11Updated: 2026-05-11

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

RecruitingNCT06927739

AbcentraAcute Coronary Syndromes, Atherosclerotic Coronary Vascular Disease, Coronary Arterial Disease (CAD) +3

Start: 2025-08-11End: 2027-06-01Target: 240Updated: 2026-01-27

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Orticumab in Participants with Prior Myocardial Infarction who have Elevated Coronary Inflammation Based on Fat Attenuation Index (FAI) Score Assessed by Coronary Computed Tomography Angiography (CCTA)

RecruitingCTIS2025-520464-17-00

Abcentra LLCAtherosclerotic Cardiovascular disease

Start: 2025-10-21Target: 184Updated: 2025-11-03